{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008293","form_type":"8-K","ticker":null,"cik":"0001261249","company_name":"AGILE THERAPEUTICS INC","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.642950+00:00","generated_at":"2026-06-01T22:42:17.500530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agile Therapeutics Q1 net revenue $5.7M (+58% QoQ); GAAP net income of $1.3M","bullets":["Net revenue $5.7M (+58% QoQ, +50% YoY); GAAP net income $1.3M ($0.28/share) vs. net loss $4.5M in Q4 2023.","Twirla demand 81,088 cycles (+18% QoQ, +80% YoY); factory sales 70,662 cycles (+3% QoQ, +63% YoY).","Operating expenses $6.8M (-20% YoY); cash $2.6M as of March 31, 2024.","Stock now trading on OTC market under symbol AGRX; exploring strategic opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008293","json":"https://secwatch.observer/filing/0001558370-24-008293.json","markdown":"https://secwatch.observer/filing/0001558370-24-008293.md","text":"https://secwatch.observer/filing/0001558370-24-008293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1261249/000155837024008293/0001558370-24-008293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1261249/000155837024008293/agrx-20240515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:42:17.500530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42fa02fc4cad2dd0f513c002ef62683b9134a654","claim":"AGILE THERAPEUTICS INC reported three months ended March 31, 2024 results: revenue $5.7 million, net income $1.3 million, EPS $0.28 per share.","evidence_excerpt":"Net Revenue: In the first quarter 2024, the Company realized net product sales revenue of $5.7 million, a 58% increase from the fourth quarter 2023 and an increase of 50% as compared to the first quarter of 2023 net revenue of $3.8 million. ● Cost of Goods Sold (COGS) : Cost of goods sold, which consists of direct and indirect costs related to the manufacturing of Twirla, were $1.7 million for the first quarter 2024 compared to the $2.2 million for the fourth quarter 2023 and compared to the $2.0 million for the first quarter 2023. ● Total operating expenses: Total GAAP operating expenses were $6.8 million for the quarter ended March 31, 2024, compared to the $5.5 million for the fourth quarter 2023 and compared to $8.5 million for the comparable period in 2023 – a decrease of 20%. ● GAAP Net income (loss): GAAP net income was $1.3 million, or $0.28 per share, for the quarter ended March 31, 2024, compared to a GAAP net loss of $4.5 million, or $1.51 per share, for the fourth quarter 2","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1261249/000155837024008293/0001558370-24-008293-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$5.7 million"},{"label":"Net income","value":"$1.3 million"},{"label":"EPS","value":"$0.28 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}